Please login to the form below

Not currently logged in
Email:
Password:

BCMA-targeting therapy

This page shows the latest BCMA-targeting therapy news and features for those working in and with pharma, biotech and healthcare.

BMS and bluebird bio gain FDA approval for multiple myeloma therapy

BMS and bluebird bio gain FDA approval for multiple myeloma therapy

Abecma is a CAR T cell therapy approved for pre-treated myeloma patients. ... The US Food and Drug Administration (FDA) has approved Bristol Myers Squibb (BMS) and bluebird bio’s BCMA-targeting CAR T cell therapy Abecma – previously known as ide-cel

Latest news

  • bluebird bio to separate oncology and rare diseases units bluebird bio to separate oncology and rare diseases units

    Oncology Newco will assume responsibility for a number of bluebird bio’s current oncology assets, including its investigational BCMA-targeting CAR T therapy idecabtagene vicleucel (ide-cel), which is currently being ... In addition, Oncology Newco will

  • Bluebird bio leans on pipeline and Zynteglo launch as revenues fall Bluebird bio leans on pipeline and Zynteglo launch as revenues fall

    Bluebird is in partnership with BMS for a BCMA-targeting cell therapy – bb2121 or ide-cel – which recently demonstrated positive top-line results in multiple myeloma. ... Aside from the mixed figures, bluebird is looking forward and focusing on the

  • FDA begins speedy review of BMS’ CAR-T liso-cel FDA begins speedy review of BMS’ CAR-T liso-cel

    or whose disease has relapsed,” said Stanley Frankel, senior vice president, cellular therapy development, BMS. ... In addition to liso-cel, BMS has another CAR-T therapy in the pipeline – its bluebird bio-partnered BCMA-targeting therapy bb2121 for

  • J&J and Bristol-Myers Squibb/Bluebird bio reveal rival CAR-T data J&J and Bristol-Myers Squibb/Bluebird bio reveal rival CAR-T data

    Both candidates are being studied in multiple myeloma. Johnson and Johnson and Bristol-Myers Squibb/Bluebird bio have both revealed data from their respective BCMA-targeting CAR-T therapies in multiple ... BMS/Bluebird also had their own CAR-T data in

  • GSK preps filings for BCMA-targeting multiple myeloma drug GSK preps filings for BCMA-targeting multiple myeloma drug

    GSK2857916 is one of a slew of BCMA-targeting therapies coming through the biopharma industry pipeline, jostling for position with a CAR-T therapy from Celgene and Bluebird Bio called bb2121 ... It is the most advanced BCMA-targeting ADC in development,

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

Guide
How to embrace behavioural science principles in healthcare MR...
Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...